Contineum Therapeutics (NASDAQ: CTNM) grants director 19,000 stock options

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Contineum Therapeutics director Todd R. Brady received a grant of stock options for 19,000 shares of Class A Common Stock. The options have a $14.19 exercise price, were granted under the 2024 Equity Incentive Plan, and vest in full on June 26, 2027 or at the next annual stockholder meeting.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Brady Todd R.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	19,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 19,000 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Option grant size: 19,000 shares Exercise price: $14.19 per share Post-grant derivative holdings: 19,000 options +1 more

4 metrics

Option grant size 19,000 shares Stock Option (right to buy) for Class A Common Stock

Exercise price $14.19 per share Conversion/exercise price of granted stock options

Post-grant derivative holdings 19,000 options Total stock options following transaction

Option expiration June 25, 2036 Expiration date of director stock options

Key Terms

Stock Option (right to buy), 2024 Equity Incentive Plan, Non-Employee Director Compensation Program, Class A Common Stock, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

2024 Equity Incentive Plan financial

"Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan")"

Non-Employee Director Compensation Program financial

"pursuant to the Issuer's Non-Employee Director Compensation Program, as amended"

Class A Common Stock financial

"a stock option under the Plan for 19,000 shares of the Company's Class A Common Stock"

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

vest in full financial

"Option will vest in full on the earlier of (i) June 26, 2027"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/26/2026 - 05:43 PM Accepted by SEC EDGAR 06/26/2026 - 05:43 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Brady Todd R.

(Last)

(First)

(Middle)

3565 GENERAL ATOMICS COURT, SUITE 200

(Street)

SAN DIEGO

CALIFORNIA

92121

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Contineum Therapeutics, Inc. [ CTNM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$14.19	06/26/2026		A		19,000		⁽¹⁾	06/25/2036	Class A Common Stock	19,000	$0	19,000	D

Explanation of Responses:

1. Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 19,000 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2027, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service.

Remarks:

	/s/ Peter Slover, Attorney-in-Fact	06/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Contineum Therapeutics (CTNM) director Todd R. Brady receive in this Form 4?

Todd R. Brady received a grant of stock options for 19,000 shares of Class A Common Stock. These options were issued under Contineum’s 2024 Equity Incentive Plan as part of its Non-Employee Director Compensation Program after the regular annual stockholder meeting.

What is the exercise price of the Contineum Therapeutics (CTNM) options granted to Todd R. Brady?

The granted stock options have an exercise price of $14.19 per share. This means Brady can purchase up to 19,000 Class A shares at $14.19, regardless of market price, once the options vest and before they expire on June 25, 2036.

When do Todd R. Brady’s Contineum Therapeutics (CTNM) stock options vest?

The options vest in full on the earlier of June 26, 2027 or the next regular annual meeting of stockholders. Vesting is also conditioned on Brady’s continuous service as a non-employee director on the company’s Board of Directors through that vesting date.

How were the 19,000 Contineum Therapeutics (CTNM) options determined for Todd R. Brady?

The 19,000-share option grant is automatic under Contineum’s Non-Employee Director Compensation Program. After each regular annual stockholder meeting, every continuing non-employee director is granted a stock option for 19,000 shares under the company’s 2024 Equity Incentive Plan.

What is the expiration date of the Contineum Therapeutics (CTNM) options granted to Todd R. Brady?

The stock options are scheduled to expire on June 25, 2036. Brady can exercise the options for up to 19,000 Class A shares at $14.19 per share any time after vesting and before this expiration date, subject to plan terms.